51371-55-2

Usage

Uses

Used in Organic Synthesis:
(E)-Ethyl 4-Bromo-3-methyl-2-butenoate is used as a synthetic intermediate for the production of various organic compounds. Its unique structure allows it to be a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (E)-Ethyl 4-Bromo-3-methyl-2-butenoate is used as a key component in the development of new drugs. Its chemical properties make it suitable for the creation of novel molecules with potential therapeutic applications.
Used in Agrochemical Industry:
(E)-Ethyl 4-Bromo-3-methyl-2-butenoate is also utilized in the agrochemical industry for the synthesis of new pesticides and other crop protection agents. Its structural features can be exploited to design compounds with improved efficacy and selectivity.
Used in Specialty Chemicals:
In the specialty chemicals sector, (E)-Ethyl 4-Bromo-3-methyl-2-butenoate is employed as a versatile intermediate for the production of various high-value chemicals, such as fragrances, dyes, and additives for the plastics and coatings industries.

Upstream product

• 65527-85-7 ethyl (E)-4-hydroxy-3-methyl-2-butenoate 
• 541-47-9 3-Methylbutenoic acid 
• 33537-17-6 ethyl 2-hydroxy-3-methyl-3-butenoate 
• 638-10-8 ethyl 3-methylbut-2-enoate 
• 70423-43-7 (E)-Ethyl-4-hydroxy-3-methylbut-2-enoate 
• 138777-15-8 ethyl 4-{[tert-butyl(dimethyl)silyl]oxy}-3-methyl-2-butenoate 
• 62054-49-3 ethyl (E)-3-formyl-2-butenoate 

Downstream Products

• 100450-35-9 (+/-)-6-chloromethyl-4-methyl-5,6-dihydro-pyran-2-one 
• 100612-56-4 ethyl 3-methyl-4-phenoxybut-2-enoate 
• 109515-03-9 3-methyl-4-phthalimido-crotonic acid ethyl ester 
• 13058-12-3 ethyl 3,7-dimethyl-2,6-octadienoate 
• 51318-38-8 (E)-4-[4-(4-Chloro-phenoxy)-phenoxy]-3-methyl-but-2-enoic acid ethyl ester 
• 39760-56-0 triethyl 3-methyl-4-phosphonocrotonate 
• 51318-22-0 (E)-4-(4-Benzyloxy-phenoxy)-3-methyl-but-2-enoic acid ethyl ester 
• 52918-08-8 (E)-3-Methyl-4-(4-phenoxy-phenoxy)-but-2-enoic acid ethyl ester 
• 51318-20-8 (E)-4-(4-Cyclohexyloxy-phenoxy)-3-methyl-but-2-enoic acid ethyl ester 
• 71843-42-0 (E)-4-[5-Methoxy-1,5-dimethyl-hex-(E)-ylideneaminooxy]-3-methyl-but-2-enoic acid ethyl ester 
• 51318-51-5 (E)-4-[4-(4-Ethoxy-phenoxy)-phenoxy]-3-methyl-but-2-enoic acid ethyl ester 
• 1617-19-2 3-methyl-but-3-enoic acid ethyl ester 
• 15898-66-5 3,6-dimethyl-octa-2,6-dienedioic acid diethyl ester 
• 97361-72-3 3-Methyl-4--crotonsaeureethylester 

Relevant academic research and scientific papers

NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

THERAPEUTIC COMPOUNDS

The invention provides compounds formula (I) and salts thereof: wherein the bond represented by ---- is a single bond or a double bond, and R1 has any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.

Multifunctional Cyclopentadienes as a Scaffold for Combinatorial Bioorganometallics in [(η5-C5H2R1R2R3)M(CO)3] (M=Re, 99mTc) Piano-Stool Complexes

Multifunctional cyclopentadiene (Cp) ligands and their rhenium and 99mTc complexes were prepared by a versatile synthetic route. The properties of these Cp ligands can be tuned on demand, either during their synthesis (variation of R1) or through post-synthetic functionalization with two equal or different vectors (V1 and V2). Variation of these groups enables a combinatorial approach in the synthesis of bioorganometallic complexes. This is demonstrated by the preparation of Cp ligands containing both electron-donating and electron-withdrawing groups at the R1 position and their subsequent homo- or heterofunctionalization with biovector models (benzylamine and phenylalanine) under standard amide bond-formation conditions. All ligands can be coordinated to the fac-[Re(CO)3]+ and fac-[99mTc(CO)3]+ cores to give tetrafunctional complexes in straightforward and functional-group-tolerant procedures. The 99mTc complexes were prepared in one step, in 30 min, and under aqueous conditions from generator-eluted [99mTcO4]?.

PROCESS FOR THE SYNTHESIS OF (2E, 4E, 6Z, 8E)-8-(3,4-DIHYDRONAPHTHALEN-1(2H)-YLIDENE)-3,7-DIMETHYLOCTA-2, 4, 6-TRIENOIC ACID

This invention relates to a novel method for the synthesis of (2E,4E,6Z,8E)-8-(3,4- dihydronaphthalen-1 (2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid. In particular, the invention relates to several improvements in several individual steps of the multi- step synthesis scheme

METHOD FOR SYNTHESIS OF 9-CIS-BETA-CAROTENE AND FORMULATIONS THEREOF

The present invention relates to a method for total chemical synthesis of 9-cis-β-carotene (9CBC), and further provides stable formulations thereof.

METHOD FOR PRODUCING 4-HALOSENECIOIC ACID DERIVATIVE

In addition the present invention refers to high yield and a low cost method for preparing derivatives hour Osan which it counts 4-halo in provides. General formula (1) : (in formula, the protector for a difference from an R) the reel alcohol which will know derivatives represented by, characterized by reacting a halogenating agent, general formula (2) : (in formula, R the equal to the meanings exhibits, for a difference from an represent halogen X) represented by derivatives of 4-halo hour Osan which it counts is manufacturing method.

Iron-catalyzed aerobic C-H functionalization of pyrrolones

The aerobic oxidation of pyrrolones catalyzed by Fe(OTf)3 to form reactive N-acyliminium ion intermediates that undergo nucleophilic additions with alcohols to give the corresponding products in moderate to good yields is described.

Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers

(2E,4E,6Z,8Z)-8-(3′,4′-Dihydro-1′(2H)-naphthalen-1′-ylidene)-3,7-dimethyl-2,3,6-octatrienoinic acid (UAB30) is currently undergoing clinical evaluation as a novel cancer prevention agent. In efforts to develop even more highly potent rexinoids that prevent breast cancer without toxicity, we further explore here the structure-activity relationship of two separate classes of rexinoids. UAB30 belongs to the class II rexinoids and possesses a 9Z-tetraenoic acid chain bonded to a tetralone ring, whereas the class I rexinoids contain the same 9Z-tetraenoic acid chain bonded to a disubstituted cyclohexenyl ring. Among the 12 class I and class II rexinoids evaluated, the class I rexinoid 11 is most effective in preventing breast cancers in an in vivo rat model alone or in combination with tamoxifen. Rexinoid 11 also reduces the size of established tumors and exhibits a therapeutic effect. However, 11 induces hypertriglyceridemia at its effective dose. On the other hand rexinoid 10 does not increase triglyceride levels while being effective in the in vivo chemoprevention assay. X-ray studies of four rexinoids bound to the ligand binding domain of the retinoid X receptor reveal key structural aspects that enhance potency as well as those that enhance the synthesis of lipids.

The absolute configuration of the pyrrolosesquiterpenoid glaciapyrrol A

The total syntheses of the structurally unique and moderately cytotoxic pyrrolosesquiterpenoid glaciapyrrol A that has been isolated from a marine streptomycete by Macherla et al.1 and of seven of its stereoisomers have been performed from geraniol or nerol, respectively, using a known diastereoselective Ru-catalysed approach for the synthesis of tetrahydrofurans previously reported by Stark and co-workers.5 Comparison of 1H and 13C NMR data unambiguously clarified the relative configuration of natural glaciapyrrol A that was previously only partly solved from the available NMR data. An enantioselective synthesis was carried out resulting in the unnatural enantiomer (11S,12R,15R)-(-)-glaciapyrrol A. These data establish the absolute configuration of the natural product as (11R,12S,15S)-(+)-glaciapyrrol A.

Synthesis and herbicidal activity of diphenyl ether derivatives containing unsaturated carboxylates

A series of novel diphenyl ether derivatives containing unsaturated carboxylates were designed and synthesized. Their structures were identified by 1H nuclear magnetic resonance and elemental analyses. The bioassays indicated that the compounds 5b and 5c exhibited good herbicidal activities against velvetleaf at a concentration of 30-40 g/hm2. The relationship between structure and herbicidal activity was also discussed. Among unsaturated carboxylates group, butenoate is the most promising one. Amonst them, 4-ethoxy-4-oxobutenyl 5-(2-chloro-4-(trifluoromethyl)phenoxy)-2- nitrobenzoate 5b was identified as the most promising candidate due to its high protoporphyrinogen IX oxidase inhibition effect (pI50 = 6.64) and good herbicidal activity against broadleaf weeds with selectivity to soybean and low toxicity to mammals.